Registry update — unassessed
Comparative Study of Tirzepatide vs Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Trial registry update: COMPLETED. No results reported in the supplied registry record.
OBSERVATIONALMinor significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 18, 2026 · Discovered: Sep 23, 2026 · Assessed: — · Research update
What it does not prove
- Observational design with insurance claims data cannot establish causal effects or rule out unmeasured confounding; differences between drug groups may reflect treatment selection patterns rather than drug effects
- Emulating trial design in observational data does not overcome the fundamental limitations of non-randomised comparisons or ensure comparable baseline characteristics across groups
- The abstract does not report outcomes, effect sizes, or sample characteristics, preventing verification of findings or assessment of generalisability
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Observational
- Sample size
- —
- Duration
- —
- Population
- Participants with Type 2 Diabetes
- Primary outcome
- Major Cardiovascular Events
- Effect size
- —
- Significance
- Not reported
- Journal
- Brigham and Women's Hospital
- Published
- Sep 18, 2026
Sources
Primary source
- Brigham and Women's Hospital ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
This cohort study was initiated to emulate the design of the SURPASS-CVOT trial using observational analogues of the trial design components in a study based on insurance claims data.
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.